Organogenesis (ORGO) to Release Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is anticipated to announce its earnings results after the market closes on Thursday, February 27th. Analysts expect Organogenesis to post earnings of ($0.03) per share and revenue of $109.60 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Organogenesis Stock Down 0.9 %

Shares of NASDAQ ORGO opened at $3.18 on Tuesday. The company has a 50 day simple moving average of $3.38 and a 200 day simple moving average of $3.21. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. Organogenesis has a 1 year low of $2.16 and a 1 year high of $4.57. The firm has a market cap of $399.81 million, a PE ratio of -53.00 and a beta of 1.77.

Insider Activity

In related news, CEO Gary S. Gillheeney sold 55,615 shares of Organogenesis stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the transaction, the chief executive officer now directly owns 3,044,779 shares of the company’s stock, valued at $10,230,457.44. The trade was a 1.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 278,116 shares of company stock valued at $991,190. Insiders own 36.90% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.